# INCYTE CORP (INCY) — litigation/settled [announced]
Source: SEC API (secapi.ai) · situation sit_aab754a894a908f916dd · retrieved 2026-08-11T16:03:51.200Z

## Overview
Incyte Corporation is a biopharmaceutical company that develops and commercializes first-in-class and next-generation medicines across Hematology, Oncology, and Inflammation and Autoimmunity franchises, with marketed products including Jakafi (ruxolitinib), Opzelura (ruxolitinib cream), and Monjuvi/Minjuvi (tafasitamab).

Incyte Corporation completed its acquisition of Vega Therapeutics, Inc., a wholly owned subsidiary of Star Therapeutics, LLC, in July 2026. Under the stock purchase agreement, Incyte acquired all outstanding shares of Vega Therapeutics for $1.25 billion in upfront consideration. Star Therapeutics is eligible to receive up to $750 million in additional payments contingent upon the achievement of sales milestones. The acquisition adds latarcibart, a novel investigational monoclonal antibody in Phase 3 development for von Willebrand disease (VWD), to Incyte's late-stage pipeline.

## Terms
- Counterparty: Vega Therapeutics, Inc. (subsidiary of Star Therapeutics, LLC) · Deal value: $1.25B · Consideration: cash

## Key dates
- Announced 2026-07-28

## Timeline
- 2026-07-28 · 8-K (0000879169-26-000053): 8-K - INCYTE CORP — *Incyte Corporation is a biopharmaceutical company that develops and commercializes first-in-class and next-generation medicines across Hematology, Oncology, and Inflammation and Autoimmunity franchises, with marketed products including Jakafi (ruxolitinib), Opzelura (ruxolitinib cream), and Monjuvi/Minjuvi (tafasitamab).* Incyte Corporation completed its acquisition of Vega Therapeutics, Inc., a wholly owned subsidiary of Star Therapeutics, LLC, in July 2026. Under the stock purchase agreement, Incyte acquired all outstanding shares of Vega Therapeutics for $1.25 billion in upfront consideration. Star Therapeutics is eligible to receive up to $750 million in additional payments contingent upon the achievement of sales milestones. The acquisition adds latarcibart, a novel investigational monoclonal antibody in Phase 3 development for von Willebrand disease (VWD), to Incyte's late-stage pipeline.
  https://www.sec.gov/Archives/edgar/data/879169/0000879169-26-000053.txt

## Citations
- 0000879169-26-000053 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000087916926000053